These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22194440)

  • 21. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.
    Demidenko ZN; Vivo C; Halicka HD; Li CJ; Bhalla K; Broude EV; Blagosklonny MV
    Cell Death Differ; 2006 Sep; 13(9):1434-41. PubMed ID: 16311509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
    Powers MV; Clarke PA; Workman P
    Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
    Newcomb EW; Lukyanov Y; Schnee T; Esencay M; Fischer I; Hong D; Shao Y; Zagzag D
    Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
    Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
    Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
    Lukasiewicz E; Miekus K; Kijowski J; Gozdzik J; Wilusz M; Bobis-Wozowicz S; Wiecha O; Majka M
    J Physiol Pharmacol; 2009 Sep; 60(3):161-6. PubMed ID: 19826195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
    Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
    Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
    Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
    Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
    Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
    J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
    Reikvam H; Nepstad I; Sulen A; Gjertsen BT; Hatfield KJ; Bruserud Ø
    Expert Opin Investig Drugs; 2013 May; 22(5):551-63. PubMed ID: 23586877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of heat shock protein 90 under chemical hypoxic conditions protects cardiomyocytes against injury induced by serum and glucose deprivation.
    Wu K; Xu W; You Q; Guo R; Feng J; Zhang C; Wu W
    Int J Mol Med; 2012 Nov; 30(5):1138-44. PubMed ID: 22922826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concerted actions of multiple transcription elements confer differential transactivation of HSP90 isoforms in geldanamycin-treated 9L rat gliosarcoma cells.
    Chao CC; Sun FC; Wang CH; Lo CW; Chang YS; Chang KC; Chang MD; Lai YK
    J Cell Biochem; 2008 Jul; 104(4):1286-96. PubMed ID: 18320580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV; Li Y; Younes A
    Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A; Asano T; Ito K; Asano T
    Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.